We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, an... Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. Show more
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0432 | 12.5508425334 | 0.3442 | 0.4773 | 0.32 | 2407851 | 0.43819482 | CS |
4 | 0.1014 | 35.4545454545 | 0.286 | 0.5195 | 0.2257 | 3494362 | 0.34727121 | CS |
12 | 0.1114 | 40.3623188406 | 0.276 | 0.5195 | 0.2257 | 1534743 | 0.33583842 | CS |
26 | 0.0873 | 29.0903032323 | 0.3001 | 0.5195 | 0.2257 | 1005414 | 0.33445746 | CS |
52 | -0.3059 | -44.1223135728 | 0.6933 | 1.15 | 0.2257 | 844304 | 0.46306277 | CS |
156 | -12.2926 | -96.9447949527 | 12.68 | 13.965 | 0.2257 | 719347 | 3.9171407 | CS |
260 | -16.1926 | -97.6634499397 | 16.58 | 29.6473 | 0.2257 | 725761 | 8.95077668 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions